Azithromycin for acute bronchitis: a randomised, double-blind, controlled trial

Autor:	Yue Wang, Laura S. Sadowski, Lakshmi Durairaj, Arthur T. Evans, Marjorie Charles-Damte, Shahid Husain
Rok vydání:	2002
Předmět:	Adult Male medicine.medical_specialty Ascorbic Acid Azithromycin law.invention Double-Blind Method Randomized controlled trial law Surveys and Questionnaires Internal medicine Humans Medicine Bronchitis Adverse effect Aged Antibacterial agent Aged 80 and over Analysis of Variance Chi-Square Distribution Intention-to-treat analysis business.industry Inhaler General Medicine Middle Aged Ascorbic acid medicine.disease Anti-Bacterial Agents Surgery Treatment Outcome Acute Disease Quality of Life Female business medicine.drug
Zdroj:	The Lancet. 359:1648-1654
ISSN:	0140-6736
DOI:	10.1016/s0140-6736(02)08597-5
Popis:	Summary Background The value of azithromycin for treatment of acute bronchitis is unknown, even though this drug is commonly prescribed. We have investigated this question in a randomised, double-blind, controlled trial. Methods Adults diagnosed with acute bronchitis, without evidence of underlying lung disease, were randomly assigned azithromycin (n=112) or vitamin C (n=108) for 5 days (total dose for each 1·5 g). All individuals were also given liquid dextromethorphan and albuterol inhaler with a spacer. The primary outcome was improvement in health-related quality of life at 7 days; an important difference was defined as 0·5 or greater. Analysis was by intention to treat. Findings The study was stopped by the data-monitoring and safety committee when 220 patients had been recruited. On day 7, the adjusted difference in health-related quality of life was small and not significant (difference 0·03 [95% CI -0·20 to 0·26], p=0·8). 86 (89%) of 97 patients in the azithromycin group and 82 (89%) of 92 in the vitamin C group had returned to their usual activities by day 7 (difference 0·5% [−10% to 9%], p>0·9). There were no differences in the frequency of adverse effects; three patients in the vitamin C group discontinued the study medicine because of perceived adverse effects, compared with none in the azithromycin group. Most patients (81%) reported benefit from the albuterol inhaler. Interpretation Azithromycin is no better than low-dose vitamin C for acute bronchitis. Further studies are needed to identify the best treatment for this disorder.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2f4a6b257e773106053bef49c31cd63a https://doi.org/10.1016/s0140-6736(02)08597-5 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.